earnings
Gilead Raises Sales Guidance: Strong Demand Offsets Transaction Costs (GILD Q1 2026 Earnings Call)
Gilead Sciences reported a strong start to the fiscal year, driven by robust demand for its HIV and oncology therapies.
Gilead Sciences reported a strong start to the fiscal year, driven by robust demand for its HIV and oncology therapies.